1. Home
  2. LPG vs TBPH Comparison

LPG vs TBPH Comparison

Compare LPG & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dorian LPG Ltd.

LPG

Dorian LPG Ltd.

HOLD

Current Price

$29.40

Market Cap

1.1B

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$18.99

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPG
TBPH
Founded
2013
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
LPG
TBPH
Price
$29.40
$18.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$35.00
$27.80
AVG Volume (30 Days)
530.3K
376.6K
Earning Date
02-05-2026
02-25-2026
Dividend Yield
10.84%
N/A
EPS Growth
N/A
N/A
EPS
2.23
0.58
Revenue
$359,008,462.00
$80,327,000.00
Revenue This Year
$29.52
$70.78
Revenue Next Year
N/A
N/A
P/E Ratio
$13.26
$32.64
Revenue Growth
N/A
27.12
52 Week Low
$16.66
$7.90
52 Week High
$32.79
$21.03

Technical Indicators

Market Signals
Indicator
LPG
TBPH
Relative Strength Index (RSI) 65.23 46.33
Support Level $27.13 $18.83
Resistance Level $28.88 $21.03
Average True Range (ATR) 0.91 0.83
MACD 0.07 -0.18
Stochastic Oscillator 72.33 22.14

Price Performance

Historical Comparison
LPG
TBPH

About LPG Dorian LPG Ltd.

Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece. IT operates in one reportable segment, the international transportation of LPG.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: